Genesis Drug Discovery & Development appointed Olesia Buiakova, M.D., Ph.D., as chief scientific officer. Dr. Buiakova began her career with Genesis Biotechnology Group as VP of biology for Invivotek in 2013. Later that year, she transitioned into her role as chief scientific officer of Invivotek. Genesis is the CRO of Genesis Biotechnology Group.

Olesia Buiakova

Dr. Paul Harney has become president, North America, for Prescient Healthcare Group. He also joined Prescient’s board of directors. Dr. Harney comes to Prescient after spending more than 20 years providing guidance and support to the healthcare industry. Since completing his Ph.D. in chemistry at Stony Brook University, he has held leadership roles at various firms including Deloitte Consulting, Quintiles and IQVIA. At Prescient, he is responsible for enhancing and delivering the company’s U.S. growth strategy and ensuring high levels of client satisfaction. Prescient is a biopharma product and portfolio strategy firm.

Brian Guy has become president of Breckenridge Pharmaceutical. Guy previously served as senior VP, Business Operations, and has been with the company since 2012. Prior to his employment with Breckenridge, Guy served in senior business development and operations roles in the pharma industry. He succeeds Larry Lapila, who retired from his position as president. Breckenridge is a privately held own-label generic pharmaceutical R&D company.

Syntactx – a CRO that specializes in medical device, pharmaceutical and genetics clinical trials – has appointed Marlene Barton to VP, department head, regulatory affairs; Chie Iwaishi to senior director, regulatory affairs; and Darlene Garner to manager, regulatory affairs.